Following guidance from u.s. food & drug administration in type-c meeting lipella pharmaceuticals to advance lead product candidate to phase 2b

Company to initiate phase 2b clinical trial in lead asset, lp-10 in 2h 2024 pittsburgh, pa, may 21, 2024 – lipella pharmaceuticals inc. (nasdaq: lipo) (“lipella” or the “company”), a clinical-stage biotechnology company, announced today the receipt of u.s. food & drug administration (“fda”) type-c meeting guidance regarding the lp-10 (liposomal tacrolimus) clinical program.
LIPO Ratings Summary
LIPO Quant Ranking